{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:37:21Z","timestamp":1785879441245,"version":"3.56.0"},"reference-count":26,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To evaluate the effectiveness of vinorelbine in the management of various malignant tumor types in dogs.<\/jats:p>\n<jats:p><jats:bold>Design<\/jats:bold>\u2014Retrospective case series.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u201458 dogs with malignant tumors, including pulmonary carcinoma (n = 31), histiocytic sarcoma (9), mast cell tumor (5), lymphoma (4), melanoma (2), and 7 other tumor types (1 each).<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014Medical records of dogs treated with vinorelbine from December 1997 to December 2012 were reviewed for data regarding signalment, clinical signs, physical examination findings, clinicopathologic test results, diagnostic imaging results, vinorelbine doses and dose frequency, surgery and radiotherapy details when applicable, other chemotherapeutics administered, and outcomes. Descriptive, comparative, and survival statistics were computed for all dogs and for dogs by histologic subgroup of tumors.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Vinorelbine was administered palliatively to 44 (76%) dogs. One (2%) dog had a complete response for 162 days, 5 (11%) dogs had a partial response for a median duration of 91 days, 19 (43%) dogs had stable disease for a median duration of 68 days, and 19 (43%) dogs developed progressive disease after a median duration of 21 days. Clinical benefit was more difficult to assess in the remaining 14 (24%) dogs that received vinorelbine as an adjuvant treatment. Overall median time to tumor progression was 103 days (range, 5 to 1,533 days).<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Vinorelbine appeared to be effective in the treatment of several tumor types in dogs. Follow-up prospective studies of the clinical benefit of the drug in specific clinical scenarios will be necessary to support this conclusion.<\/jats:p>","DOI":"10.2460\/javma.246.11.1230","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T18:23:31Z","timestamp":1431541411000},"page":"1230-1237","source":"Crossref","is-referenced-by-count":45,"title":["Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997\u20132012)"],"prefix":"10.2460","volume":"246","author":[{"given":"Raelene M.","family":"Wouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairin E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Cancer chemotherapy and biotherapy: principles and practice","first-page":"216","article-title":"Chapter 13: antimitotic drugs","author":"Rowinsky","year":"2011"},{"key":"ref2","series-title":"Navelbine (vinorelbine tartrate) prescribing information [package insert]","year":"2002"},{"key":"ref3","series-title":"Anticancer Drugs","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00001813-199308000-00014","article-title":"Pharmacokinetics of Navelbine after oral administration in the dog and the monkey","volume":"4","author":"Zhou","year":"1993"},{"key":"ref4","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1939-1676.2004.tb02581.x","article-title":"Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia","volume":"18","author":"Poirier","year":"2004"},{"key":"ref5","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1939-1676.2008.0051.x","article-title":"A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors","volume":"22","author":"Grant","year":"2008"},{"key":"ref6","series-title":"Vet Comp Oncol","article-title":"Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma [published online ahead of print Aug 25, 2013]","author":"Kaye"},{"key":"ref7","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/jvim.12101","article-title":"Phase I clinical trial of vinorelbine in tumor-bearing cats","volume":"27","author":"Pierro","year":"2013"},{"key":"ref8","series-title":"Expert Rev Anticancer Ther","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737140.2014.866041","article-title":"Management of advanced or recurrent cervical cancer: chemotherapy and beyond","volume":"14","author":"Elit","year":"2014"},{"key":"ref9","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1006\/gyno.2000.6089","article-title":"Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma","volume":"81","author":"S\u00f8rensen","year":"2001"},{"key":"ref10","series-title":"Anticancer Res","first-page":"1383","article-title":"Neoadjuvant carboplatin and vinorelbine followed by radiotherapy in locally advanced head and neck or esophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status","volume":"28","author":"Koussis","year":"2008"},{"key":"ref11","series-title":"Cancer Invest","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/07357900600705268","article-title":"A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma","volume":"24","author":"Kulke","year":"2006"},{"key":"ref12","series-title":"Lung Cancer","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.lungcan.2011.04.014","article-title":"Chemotherapy and targeted therapies for unresectable malignant mesothelioma","volume":"73","author":"Kelly","year":"2011"},{"key":"ref13","series-title":"Ann Hematol","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00277-005-0058-0","article-title":"Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral stem cells in patients with multiple myeloma","volume":"85","author":"Annunziata","year":"2006"},{"key":"ref14","series-title":"Hematol Oncol","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/hon.2011","article-title":"Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma","volume":"30","author":"Sivam","year":"2012"},{"key":"ref15","series-title":"Ann Hematol","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00277-010-1113-z","article-title":"Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT","volume":"90","author":"Suyan\u0131","year":"2011"},{"key":"ref16","series-title":"Pediatr Blood Cancer","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/pbc.22133","article-title":"Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study","volume":"53","author":"Kuttesch","year":"2009"},{"key":"ref17","series-title":"Vet Comp Oncol","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document [published online ahead of print Mar 28, 2013]","author":"Nguyen"},{"key":"ref18","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010"},{"key":"ref19","series-title":"Vet Comp Oncol","article-title":"Veterinary Cooperative Oncology Group\u2014common terminology criteria for adverse events (VCOG-CT-CAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1 [published online ahead of print Jul 20, 2011]"},{"key":"ref20","series-title":"J Am Vet Med Assoc","first-page":"109","article-title":"Prognostic factors for tumor remission and survival in dogs after surgery for primary lung tumor: 76 cases (1975\u20131985)","volume":"195","author":"Ogilvie","year":"1989"},{"key":"ref21","series-title":"J Am Vet Med Assoc","first-page":"1422","article-title":"Evaluation of prognostic factors for dogs with primary lung tumors: 67 cases (1985\u20131992)","volume":"211","author":"McNiel","year":"1997"},{"key":"ref22","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1748-5827.2007.00403.x","article-title":"Impact of primary tumour stage on survival in dogs with solitary lung tumours","volume":"49","author":"Polton","year":"2008"},{"key":"ref23","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1476-5810.2006.00090.x","article-title":"Histiocytic sarcomas in Flat-Coated Retrievers: a summary of 37 cases (November 1998\u2013March 2005)","volume":"4","author":"Fidel","year":"2006"},{"key":"ref24","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski","year":"2007"},{"key":"ref25","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1476-5829.2009.00186.x","article-title":"Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy","volume":"7","author":"Skorupski","year":"2009"},{"key":"ref26","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1939-1676.2009.0394.x","article-title":"A survey of evidence in the Journal of Veterinary Internal Medicine oncology manuscripts from 1999 to 2007","volume":"24","author":"Sahora","year":"2010"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/246\/11\/javma.246.11.1230.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/246\/11\/javma.246.11.1230.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/246\/11\/javma.246.11.1230.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:44:56Z","timestamp":1741347896000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/246\/11\/javma.246.11.1230.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":26,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.246.11.1230","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}